These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC
41 results:

  • 1. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland.
    Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J
    Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of colorectal cancer in Tibet].
    Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
    Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
    Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Cost-Efficient Detection of
    Romanko AA; Mulkidjan RS; Tiurin VI; Saitova ES; Preobrazhenskaya EV; Krivosheyeva EA; Mitiushkina NV; Shestakova AD; Belogubova EV; Ivantsov AO; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762506
    [TBL] [Abstract] [Full Text] [Related]  

  • 6.
    Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. NTRK fusions in solid tumours: what every pathologist needs to know.
    Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
    Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Performances of the Idylla GeneFusion Assay: contribution to a rapid diagnosis of targetable gene fusions in tumour samples.
    Guillard M; Caumont C; Marcorelles P; Merlio JP; Cappellen D; Uguen A
    J Clin Pathol; 2024 Jul; 77(8):561-567. PubMed ID: 37185257
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
    Wu S; Liu Y; Shi X; Zhou W; Zeng X
    Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prevalence of NTRK Fusions in Canadian Solid Tumour cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
    Principe DR
    Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric cancer with NTRK Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
    Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
    J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer.
    Chen Z; Huang Z; Luo Y; Zou Q; Bai L; Tang G; Wang X; Cao G; Huang M; Xiang J; Yu H
    J Transl Med; 2021 Feb; 19(1):73. PubMed ID: 33593392
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic cancers.
    Tsang ES; Grisdale CJ; Pleasance E; Topham JT; Mungall K; Reisle C; Choo C; Carreira M; Bowlby R; Karasinska JM; MacMillan D; Williamson LM; Chuah E; Moore RA; Mungall AJ; Zhao Y; Tessier-Cloutier B; Ng T; Sun S; Lim HJ; Schaeffer DF; Renouf DJ; Yip S; Laskin J; Marra MA; Jones SJM; Loree JM
    Clin Cancer Res; 2021 Jan; 27(2):522-531. PubMed ID: 33148671
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.